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Factors affecting the patency of arteriovenous
fistulas for dialysis access
George E. Smith, MBBS, MRCS, Risha Gohil, MBChB, MRCS, and
Ian C. Chetter, MBChB, FRCS, MD, Hull, United Kingdom
Background: The autologous arteriovenous fistula (AVF) is the accepted gold standard mode of repeated vascular access
for hemodialysis in terms of access longevity, patient morbidity, and health care costs. This review assesses the current
evidence supporting the role of various patient and surgeon factors on AVF patency.
Methods: The literature was searched to identify the current evidence available for patient characteristics, methods of AVF
planning, and anatomic factors that may affect patency outcomes after AVF formation. The use of adjuvant medications,
surgical techniques, and policies for AVF maintenance are discussed in relation to AVF patency.
Results: Current literature supports patient factors, such as increasing age, presence of diabetes, smoking, peripheral
vascular disease, predialysis hypotension, and vessel characteristics, as directly influencing AVF patency. Vessels of small
caliber (<2 mm) or demonstrating reduced distensibility are unlikely to create a functional AVF. Current evidence does
not support altered patency due to sex or raised body mass index (<35 kg/m2). Factors such as early referral for AVF,
preoperative ultrasound vessel mapping, use of vascular staples, and intraoperative flow measurements affected AVF
patency, but the use of medical adjuvant therapies did not. Programs of surveillance and various needling techniques to
maintain patency are not supported by current evidence. Novel techniques of infrared radiotherapy and topical glyceryl
trinitrate are possible future strategies to increase AVF patency rates. The limitations of available evidence include a lack
of large, randomized controlled trials and meta-analysis data to support current practice.
Conclusions: There is a complex interaction of factors that may affect the patency of an individual AVF. These need to be
carefully considered when selecting surgical site or technique, adjuvant treatments, and follow-up protocols for AVFs.
(J Vasc Surg 2012;55:849-55.)
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aThe advent of hemodialysis in the mid-20th century
gave rise to a need for reliable, repeated access to the
circulation. Brescia and Cimino published their landmark
report describing hemodialysis through an autologous ar-
teriovenous fistula (AVF) in 1966, vastly reducing the
problems of infection and thrombosis that plagued the
previously described long-term cannulation methods and
external shunts.1 The autologous AVF has since been
widely accepted as the optimal access method for hemodi-
alysis as measured by lower morbidity and mortality figures
and reduced maintenance costs. This review summarizes
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atency.
ETHODS
We performed a search of published literature in Octo-
er 2010 using the Medline (1966 to October 2010),
mbase (1980 to October 2010), CINAHL (1982 to
ctober 2010), and Cochrane Library research databases.
he following search terms were used: haemodialysis or
emodialysis or dialysis or kidney failure or kidney disease
r arteriovenous fistula or arteriovenous shunt or access or
ascular access, or angio access and survival or patency or
utcomes.
These search results were further combined with a
earch performed for each of the subheadings below, in-
luding alternate spellings. Any studies identified as de-
cribing or possibly describing factors affecting patency or
utcome for autologous AVFs for hemodialysis in adults
ere reviewed and their reference lists searched for further
elevant studies. Reports were ranked according to design
y the Centre for Evidence-BasedMedicine (Oxford) scale,
nd data from the highest-ranked evidence available are
ncluded in this review. Where this evidence was contradic-
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March 2012850 Smith et altory or contentious, the review also includes data from
lower-ranked publications. The best available level of evi-
dence for each factor reviewed is summarized in Table I and
Table II.
RESULTS
Patient factors
Patient factors may affect the outcomes of a newly
formed AVF, and those that can be modified should be
addressed where possible. Factors that cannot be modified
may influence the choice of site or surgical technique for
AVF creation.
Age. Age could conceivably increase risk by an in-
creased incidence of comorbidities (peripheral vascular dis-
Table I. Summary evidence levels and evidence limitation
discussed
Nonmodifiable factor Level of best evidence
Best evidence su
effect on pate
Increased age Meta-analysis2 Yes
Female sex Meta-analysis5 No
Diabetes Prospective series6,7 Yes
Hypotension Prospective series12,13 Yes
Artery diameter Meta-analysis28 Yes
Arteriosclerosis Prospective series29,30 Yes
Arterial low Prospective series31-33 Yes
Venous diameter Meta-analysis28 Yes
Venous distensibility Prospective eries31,34 Yes
ABPI, Ankle-brachial pressure index; AVF, arteriovenous fistula; BMI, bod
systolic velocity; RC, radiocephalic; RI, resistive index.
Table II. Summary of evidence levels and evidence limitat
Modifiable factor Level of best evidence
Best eviden
effect on
Smoking Prospective series8-11 Yes
Obesity (BMI 30) Prospective series14 No
“Early” referral Retrospective series18 Yes
Ultrasound imaging RCT19-21 Yes
Anastomosis type RCT36 Yes
Vascular staples/clips Prospective series37,38 Yes
Flow assessments Prospective series39,40 Yes
Antiplatelet therapy Systematic
review/RCT41,42
Yes/o
Systemic heparin use RCT (see Table III) No
GTN patch therapy Controlled experiment44 Potential f
Far infrared therapy RCT45 Yes
Timing of first cannulation Prospective observational
study46
Yes
Cannulation technique Cohort studies50 No
Surveillance Meta analysis52,53 No
AVF, Arteriovenous fistula (autologous); AVG, arteriovenous graft (prostheease, diabetes, etc). A meta-analysis of 13 cohort studies (of Chich 11 were retrospective) provides the best available
vidence, concluding that wrist radiocephalic AVFs
RCAVFs) had an increased primary failure rate and re-
uced patency in elderly patients at all time points.2 How-
ver, the definitions of “elderly” in the included studies
anged from 50 to 70 years, and the review was specific to
rist AVFs. Subsequent studies have reported conflicting
ndings for the effects of patient age on outcome.
Sex. In the Hemodialysis (HEMO) Study, female sex
as identified as a significant predictor of graft rather than
VF use,3 but there is little specific evidence for AVF
atency differences between sexes. Women may present
ith smaller-caliber arteries and may therefore be expected
o have lower AVF patency rates than men. However,
vailable evidence identified for each nonmodifiable factor
s
Limitations
Meta-analysis of RC AVF only
Effect reduced in proximal AVF and with imaging
Diastolic pressure only
Reduced patency of artery
Increased failure risk with increased IMT and reduced ABPI
Higher RI or a reduced increase in PSV correlate with
poorer AVF flow and secondary patency
Lower limit of 2 mm suggested for wrist RC AVF; no
agreed figures for other sites
DUS assessments are poorly reproducible
s index; DUS, duplex ultrasound IMT, intima-media thickness; PSV, peak
for potentially modifiable factors discussed
gests
cy Limitations
Negative effect on patency in smokers
Evidence of effect seen in BMI 35
No evidence of optimal timing of referral
RCT evidence not applicable to majority of patients
End to side (or functional end to side) preferred
Can be used as prognostic tool or prompt re-evaluation in
short-term benefit but paucity of data/largest trial
found reduced thrombosis rate but no effect on
cumulative patency
Evidence suggests increased risk of bleeding with heparin
given systemically
ect Evidence of acute effect on AVF size and flow, no
evidence of effects on patency
Single RCT evidence
Cannulation before 14 days reduces patency rates
Limited data suggest shift in types of complications; no
specific data regarding patency
AVF cumulative patency does not appear to be improved
by surveillance
TN, glyceryl trinitrate; RCT, randomized prospective controlled trial.s of a
ggest
ncy
y masions
ce sug
paten
or effaplin et al4 showed that arterial and venous diameters
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Volume 55, Number 3 Smith et al 851were not significantly different between men and women.
Subsequent meta-analysis data suggest that women have
similar maturation and 1-year patency rates as men for
RCAVFs.5
Diabetes. Many centers have reported increased use of
prosthetic material for grafts in diabetic patients compared
with nondiabetic patients in their dialysis populations. De-
spite this, literature shows evidence of satisfactory AVF
outcomes in diabetic patients.6,7 Sedlacek et al6 reported
that despite increased arterial calcification, vessel diameters
and arterial peak systolic volume were not significantly
different between diabetic and nondiabetic patients in their
population. Subsequent AVF formation in their diabetic
patients was effective, and outcomes were similar regardless
of the presence of diabetes. Konner et al7 reported in-
creased use of proximal fistulas in diabetic patients but with
primary access survival similar to that of nondiabetic pa-
tients. Secondary survival at 24 months was reduced com-
pared with nondiabetic subjects, however, and steal syn-
drome was more common in the diabetic group.
Functional maturity rates for AVFs in diabetic patients have
been suggested to be increased by the use of routine vessel
mapping.7 As such, the effects of diabetes on overall AVF
outcomes may be minimized by careful preoperative vessel
imaging and AVF site selection.
Smoking. Tobacco smoking is a well-known risk fac-
tor for vascular disease and arteriosclerosis. The direct link
to AVF failure was first described by Wetzig et al,8 who
reported a significantly higher incidence of early and late
fistula failure in patients who were cigarette smokers, find-
ings that have since been confirmed by other studies.9-11
Hypotension. Postdialysis hypotension with reduced
flow through the AVF may be related to poor outcome.
Culp et al12 specifically described predialysis diastolic pres-
sure as a predictor of risk of thrombosis in AVFs and grafts
in the first year after formation. A subsequent prospective
series of 463 patients also reported that a lowmean diastolic
pressure correlated with poorer AVF survival after exclusion
of patients with early fistula failure from the study.13 Sys-
tolic pressure has not been reported to relate to access
survival.
Body mass index. Obesity is defined as body mass
index (BMI) 30 kg/m2. Some surgeons have previously
avoided AVF use in favor of grafts in obese patients, argu-
ing that even superficial veins in this groupmay be too deep
to form useable AVFs without “superficialization” or local
liposuction over the fistula.
Superficial veins are often not clinically apparent in
obese patients, and the use of preoperative imaging may
have a significant effect on the incidence, site, and patency
of AVFs in this group. A trial that used routine preoperative
imaging to compare AVF outcomes in patients with a BMI
27 vs27 kg/m2 found no difference in rates of obtain-
ing an AVF suitable for hemodialysis between the two
groups.14 Furthermore, Chan et al15 examined AVF out-
comes for 1486 hemodialysis patients and compared those
with a BMI30 vs30 kg/m2 but were unable to confirm
BMI as a factor in predicting AVF revision or failure. An Pncreased risk of failure to mature was identified for those
atients with BMI 35 kg/m2.
A small number of case reports have suggested that
xcessive soft tissue compressing venous outflow may di-
ectly lead to failure in extremely obese patients.16 The
vidence suggests that only “super obesity” affects AVF
atency and that good results can be achieved in obese
atients with awareness of specific factors (outflow occlu-
ion, need for superficialization procedures) and careful
reoperative assessment of vessels.
reoperative period
Timing of referral for AVF formation. Early referral
o access services improves the number of patients com-
encing dialysis with an AVF, improves patency, and
voids potential complications related to central venous
atheter placement.
AVF creation before dialysis is initiated may allow mat-
ration in a biochemical environment preferable to that
resent once dialysis has commenced. Uremia and dialysis
tself are associated with increased levels of oxidative stress,
recipitating endothelial dysfunction, neointimal hyperpla-
ia, and AVF stenosis. Samples of brachial vein obtained
uring access creation in 15 uremic patients showed signif-
cantly greater intimal and medial widths in patients who
ad received 6 months of dialysis compared with those
ho had received 6 months of treatment.17 In a cross-
ectional study of 750 AVFs and grafts,18 accesses placed
efore commencing dialysis had a lower failure-to-mature
ate and higher patency rate than those placed once the
atient began dialysis.
Duplex ultrasound imaging. Early studies were con-
radictory regarding the benefits of duplex ultrasound (DUS)
maging use in AVF planning. Many DUS-detectable aspects
f arterial and venous anatomy correlate with AVF patency
see below). Assessment of the subclavian waveform with
ulse-wave Doppler also gives an indication of possible
entral venous stenosis or occlusion. Two randomized con-
rolled trials have supported the use of DUS imaging over
hysical examination (PE) with 75% vs 94.4% and 80% vs
0.3% success rates for PE and DUS imaging, respectively.
owever, no sites other than RC at the level of the wrist
ere used in either study and only the laterality of site was
etermined by DUS imaging. Other significant deficien-
ies in these randomized controlled trials pertain to
utcome measures (palpable thrill at the end of the
rocedure), brevity of follow-up, and a very high rate of
oss to follow-up.19,20
Nursal et al21 randomized patients with adequate find-
ngs on PE or DUS imaging to AVF surgery and demon-
trated a nonsignificant trend toward increased palpable
hrill at day 1 in the DUS group but no significant differ-
nce in primary or cumulative patency. Wells et al22 re-
orded alteration in planned surgical sites for AVFs due to
US findings and also the assessing physician’s perception
f the need for further imaging. Results suggested that
US imaging was of little benefit in patients with adequate
E findings and that clinicians were reliably able to identify
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selected patients with insufficient clinical examination ben-
efit from DUS imaging, but DUS imaging is not needed
when the PE detects adequate vessels. Despite this, many
clinicians still use DUS imaging routinely before AVF
formation, and no trials to date have directly assessed the
use of routine vs selective DUS imaging in AVF planning.
Arterial factors
Diameter. Preoperative imaging should include as-
sessment of the arteries from the subclavian to the wrist to
document anatomic variants, patency, stenosis, and calcifi-
cation. Smaller artery diameters have been associated with
increased nonmaturation rates, but variation in exact min-
imal figures exists.23-26 Present guidelines suggest a mini-
mum diameter of 2 mm for successful AVF creation at the
wrist,27 but agreement on minimal arterial diameters for
other sites is lacking to date. This minimal value is evi-
denced by meta-analysis findings of the fistula success rate
being significantly different between radial artery diameters
2.0 mm (59%) and 2.0 mm (40%).28
Atherosclerosis. The presence of peripheral vascular
disease has been associated with an increased risk of AVF
failure. Modern high-frequency US machines capable of
high-resolution imaging can determine the intima media
thickness (IMT) of small arteries such as the radial artery at
the wrist. Ku et al29 reported that IMT measurements
during preoperative DUS imaging correlated significantly
to histologic measures and, more importantly, to AVF
thrombosis and to inadequacy of an AVF to maintain
dialysis at 1 year. Similarly, ankle-brachial pressure index, a
reliable marker for peripheral vascular disease, had a signif-
icant association with access failure after adjusting for other
variables.30
Flow and hyperemic response. The relationship be-
tween peak systolic velocity (PSV) at rest and AVF out-
comes is not clear. Dynamic measures of the potential for
increased flow have been more closely investigated. By
using spectral Doppler and induction of hand ischemia by
clenching a fist, reactive hyperemia of the arteries of the
forearm can be observed. As the fist is unclenched, an
increase in PSV and a change in flow pattern from triphasic
(high resistance) to monophasic (low resistance) is evident.
This alteration in flow can be quantified as the resistive
index or by the increase in PSV immediately after release:
Resistive index (RI)  [PSV at rest – EDV at rest]/PSV
during reactive hyperemia, with EDV representing end-
diastolic velocity.
Poor hyperemic response with an RI 0.7 was predic-
tive of immediate AVF failure in one study,31 and a higher
RI or a reduced increase in PSV with hyperemia were
correlated with reduced AVF flow at 3 months and reduced
secondary patency.31,32 The only other report of AVF
patency and change in PSV after fist clenching showed an
increase in AVF adequacy for dialysis only in women.33 renous factors
Diameter. Current guidelines suggest minimum ve-
ous diameter of 2 mm for a cephalic AVF at the wrist, and
o agreedminimummeasures exist for other sites to date.27
hesemeasures have been evidenced bymeta-analysis dem-
nstrating significant differences in fistula success rates
etween cephalic vein diameter 2.0 (71%) and 2.0 mm
29%).28
Distensibility. Venous diameters are variable with po-
ition, hydration status, temperature, and various provoca-
ion methods. Because AVFmaturation relies on increasing
enous diameter to allow cannulation, the distensibility of
eins has been investigated as a potential predictor of AVF
uccess. Malovrh31 reported that the average increase in
enous diameter in AVFs that failed was only 12% com-
ared with 48% in successful AVFs. Further studies using
train-gauge plethysmography in patients with end-stage
enal failure reported that 100% of patients with venous
istensibility of 0.50 mL/mm Hg had a nonfunctional
VF, whereas only 20% of patients with venous distensibil-
ty 0.50 mL/mm Hg had a nonfunctional AVF.34
Elastography is a recently developed technique that
ses high-frequency US to apply mechanical compression
r vibration to tissue and then detects the extent of this
eformation effect. By using simplifying assumptions, the
eformation can be interpreted as representative of the
nderlying Young’s modulus or compliance of the tissue.
iswas et al35 used this technique in assessing vein compli-
nce in the forearm, and early results suggest it may provide
etailed, high-resolution and spatially accurate maps of
ein-wall mechanics.
ntraoperative factors
Anastomosis. Three types of arteriovenous anasto-
otic arrangement can be used to establish an AVF for
ialysis: end-to-end, end-to-side, or side-to-side. Histori-
ally, AVFs were formed as first described by Brescia and
imino in their landmark report using a side-to-side anas-
omosis.1 They stated that postoperative hand swelling was
common complication. In a randomized controlled study
0 years later, Wedgwood et al36 reported that the inci-
ence of venous hypertension could be markedly reduced
ith the use of the end-to-side technique, which has now
ecome commonplace. Patency in their study was similar
etween the groups, and only the incidence of complica-
ions appeared to separate the techniques.
Vascular staples/clips. In recent years, attempts to
educe anastomotic stenosis have led to the development of
ew techniques designed to allow interrupted clipping or
tapling of vessels to increase compliance at the anastomosis
ite. Reports of such techniques have so far stated promis-
ng results of improved maturation rates in forearm autol-
gous AVFs and significantly improved patency at 40
onths in interrupted staple anastomoses.37,38
Blood flow measurement. Intraoperative blood flow
easurement, using a transit-time ultrasonic flowmeter,
egistering a flow of120mL/min, had a positive predictive
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A prior report correlated flows of 200 mL/min with
reduced primary and secondary patency.40 AVFs with low
flows after anastomosis could therefore be identified as “at
risk” and may thus warrant further investigation in the
theatre or by more intensive follow-up regimens.
Adjuvant therapies
Given that the most commonmode of AVF failure is by
thrombosis, many investigators have conducted trials of
medications for AVF patients that may reduce thrombus
formation. Others have reported the use of more novel
adjuvant therapies in attempts to increase AVF patency
rates.
Antiplatelets. The use of antiplatelets in maintaining
AVF patency was supported by the Antiplatelet Trialists’
Collaboration report.41 Cochrane Systematic Review find-
ings were generally in favor of antiplatelet therapy; how-
ever, trials show considerable heterogeneity in outcomes,
and many had only very short follow-up periods.42 A more
recent large-scale randomized, double-blind trial of the
effect of clopidogrel taken for 6 weeks after surgery dem-
onstrated a significantly lower rate of AVF thrombosis
compared with placebo.43 This reduction in thrombosis
rate did not, however, alter the rate for achieving an AVF
suitable for dialysis.
Heparin. The benefit of intravenous heparin given
intraoperatively as an anticoagulant to avoid thrombotic
complications during AVF surgery for hemodialysis has
been evaluated in three studies,44-46 with results reported
in Table III. Stouffer’s Z method allows combination of
significance measures for several trials weighted for number
of participants. Application of this method to available trial
results for use of systemic heparin suggests significantly
more frequent perioperative bleeding in patients receiving
heparin without improved AVF patency.
Topical glyceryl trinitrate. Transdermal glyceryl
trinitrate administration has been suggested as a possible
method to increase local blood flow in new AVFs. Akin et
al47 assessed fistula vein diameter in newly constructed
RCAVFs using DUS imaging with a glyceryl trinitrate
patch applied over the fistula. In the study group, diameter
and flows were significantly increased after glyceryl trini-
trate patch placement compared with measures a few hours
earlier (P  .05) but not in the control group. Increased
flow may affect maturation and early failure rate, but ran-
domized data with follow-up of outcomes are needed to
Table III. Results of randomized controlled trials of syste
Stouffer’s Z method results indicate combined significance
First author Patients Bleeding r
D’Ayala (2008)44 115
Ravari H (2008)45 198
Bhomi K (2008)46 50
Stouffer Z method (combined P)prove the effects of this therapy on patency. iFar infrared therapy. Far infrared electromagnetic
adiation has a wavelength beyond that of visible light and
s used to heat objects exposed to infrared radiation without
eating the surrounding air. Lin et al48 used far infrared
uring dialysis sessions and reported a significantly reduced
ncidence of AVF malfunction and better unassisted pa-
ency of AVFs after 1 year compared with controls. Mech-
nisms suggested relate partly to local tissue warming and
lso to improved endothelial function and an antiprolifera-
ive and anti-inflammatory effect of far infrared radiation
herapy, which has been documented in animal studies and
arly human trials.48
ostoperative period
Once created, autologous access continues to require
ngoing input frommanymembers of themultidisciplinary
eam. Aftercare, or a lack thereof, may have a significant
ffect on AVF patency.
Timing of first cannulation. Brescia and Cimino can-
ulated their pioneering AVF the first day after creation;
owever, current practice allows for a maturation period
uring which the draining vein will dilate and “arterialize”
r hypertrophy to create a durable conduit that will tolerate
epeated cannulation more readily.
The timing of the first needling can vary greatly be-
ween units and will often take into account urgency of
ialysis. Data from the Dialysis Outcomes and Practice
atterns Study (DOPPS) suggests that first cannulation
14 days after AVF formation is associated with a 2.1-fold
ncrease in the likelihood of AVF failure.49 Current consen-
us is that cannulation 14 days should be avoided,
hereas a minimum of 28 days should be allowed for AVF
aturation, the extent of which could then be assessed by
lood flow and diameter measurement in the draining
ein.27
Needling technique. Several techniques, including
ope ladder (RL), area puncture (AP), and buttonhole
BH) formation can be used for needling the AVF, but little
ata are reported regarding technique in relation to AVF
atency. The largest prospective comparison of different
eedling techniques (BH and RL) suggested that BH
atients may have more unsuccessful cannulations com-
ared with the RL method.50 The frequency of hematoma,
neurysm formation, and need for angioplasty was less in
H patients, but the incidence of infection was higher.
ecause this was a comparison of two different techniques
n two different units, bias due to other factors (expertise,
eparin use in arteriovenous fistula (AVF) surgery.
ls weighted for number of participants
ncreased P Patency rate increased P
.008 No .79
.175 Yes .046
.01 No .46
.001 No .1458mic h
leve
ate i
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Yesnfection control methods, etc) is difficult to exclude, and
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Reduced complications could be expected to improve pa-
tency, but these specific data are not available at present.
Area puncture is little researched but is generally the least-
favored technique.27
Surveillance. Thrombosis causing AVF failure is usu-
ally preceded by development of an underlying stenosis.
Consequently, the detection of stenosis in AVFs before
thrombosis could offer a strategy to improve AVF survival
by early intervention. Autologous AVF surveillance re-
search has concentrated on the use of DUS imaging, mea-
sures of access flow, and assessment of blood recirculation.
Fistula thrombosis was previously attributed to the pres-
ence of venous stenosis, and intra-access pressure ratios
(which will rise in the setting of venous stenosis) were thus
proposed to survey access function. However, fistula dys-
function or thrombosis may be due to inflow abnormalities
in 40% of cases.51 Intra-access pressure monitoringmay not
alter with inflow restriction, whereas flow measures will
detect inflow or outflow dysfunction, or both, and are thus
the current preferred method of surveillance. Surveillance
programs with regular measures of flow are designed to
detect trends over time, which may indicate progressive
stenosis at a subclinical level and instigate proactive referral
for further imaging and intervention.
Conclusions of randomized trials of AVF surveillance
are varied. Several have reported fewer thrombosed AVFs
and superior primary patency with surveillance. However,
secondary or cumulative patency was not improved by
surveillance, although an increased incidence of angiogra-
phy and angioplasty has been reported. Two recent meta-
analyses scrutinized available randomized evidence and
concluded that access blood flow monitoring may prevent
thrombosis but may not reduce the risk of access loss.52,53
Large randomized multicenter trials reporting thrombosis
rate, access loss rate, central venous catheter use, hospital-
ization or intervention rates and costs between treatment
groups are needed to definitively determine which, if any,
surveillance method should be used and the usefulness of
proactive intervention protocols.
CONCLUSIONS
Many factors that may interact to determine the success
or failure of any individual AVF, and only those for which
evidence is available in current literature are discussed in
this review and summarized in Tables II and III. These and
many more factors may need to be considered when select-
ing access sites or vessels, surgical technique, adjuvant
treatments and follow up for AVF formation.
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